Lenvervimab
Monoclonal antibody
- none
- 2055006-79-4
- FX9X4L2A2L
Lenvervimab (INN;[1] development code GC1102) is a monoclonal antibody that is being investigated for hepatitis B.[2]
This drug is being developed by GC Pharma. As of 2018[update], lenvervimab is undergoing Phase II/III trials.
References
- ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118" (PDF). WHO Drug Information. 31 (4).
- ^ Jeong GU, Ahn BY, Jung J, Kim H, Kim TH, Kim W, Lee A, Lee K, Kim JH (2020). "A recombinant human immunoglobulin with coherent avidity to hepatitis B virus surface antigens of various viral genotypes and clinical mutants". PLOS ONE. 15 (8): e0236704. Bibcode:2020PLoSO..1536704J. doi:10.1371/journal.pone.0236704. PMC 7425877. PMID 32790777.
- v
- t
- e
Monoclonal antibodies for infectious disease and toxins
Human |
|
---|
Human |
|
---|---|
Chimeric | |
Humanized |
|
Human | |
---|---|
Mouse | |
Chimeric | |
Humanized |
Human | |
---|---|
Chimeric | |
Humanized |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e